Inflation and discounts related to falling wholesale drug prices


AAmid ongoing political pressure on the pharmaceutical industry, a new analysis has found that branded drug manufacturers increased their wholesale prices by 4.4% in the second quarter of 2021, compared to real price growth a year earlier.

Meanwhile, net prices paid by health insurers for drugs, after deducting allowances such as rebates and rebates, fell 1.4%, compared to a 1.8% decrease in the second quarter of last year, according to SSR Health, a research firm that does the Pharmaceutical industry observed. Drug manufacturers, by the way, argue that net prices – not wholesale prices – are a more realistic way of assessing price changes.

Unlock this article by subscribing to STAT + and enjoy your first 30 days for free!


What is it?

STAT + is STAT’s premium subscription service for in-depth reporting and analysis across biotechnology, pharma, politics, and life sciences. Our award-winning team covers news on Wall Street, Washington policy developments, early scientific breakthroughs and clinical trial results, and healthcare disruptions in Silicon Valley and beyond.

What’s included

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerful team of reporters
  • Newsletter for subscribers only
  • Daily newsletters to keep you informed of the day’s most important industry news
  • STAT + conversations
  • Weekly opportunities to chat with our reporters and leading industry experts in live video calls
  • Exclusive industry events
  • Premium access to networking events only for subscribers across the country
  • The best reporters in the business
  • The most trusted and most connected newsroom in the healthcare industry
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools like our CRISPR Trackr.


Leave A Reply